RAS Pathway

BOSTON, July 22, 2026 Verastem Oncology has announced that the first patient has been dosed in the TARGET-D 202...

SAN DIEGO, July 13, 2026 Erasca announced updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015,...

South San Francisco, Calif. – October 30, 2025 — BridgeBio Oncology Therapeutics, Inc. (BBOT) announced two poster presentations at...